Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yi Chen, Jing Cao, Yaozhen Ye, Luting Luo, Xiaoyun Zheng, Xiaozhu Yang, Zhihong Zheng, Jing Zheng, Ting Yang & Jianda Hu. (2023) Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience. Journal of Chemotherapy 35:4, pages 322-329.
Read now
Read now
Thomas P. Thomopoulos, Anthi Bouhla, Sotirios G. Papageorgiou & Vasiliki Pappa. (2021) Chronic myelomonocytic leukemia - a review. Expert Review of Hematology 14:1, pages 59-77.
Read now
Read now
Jean S. Oak & Robert S. Ohgami. (2017) Focusing on frequent ASXL1 mutations in myeloid neoplasms, and considering rarer ASXL2 and ASXL3 mutations. Current Medical Research and Opinion 33:4, pages 781-782.
Read now
Read now
Articles from other publishers (13)
Feng-Chun Yang & Joel Agosto-Peña. (2023) Epigenetic regulation by ASXL1 in myeloid malignancies. International Journal of Hematology 117:6, pages 791-806.
Crossref
Crossref
Minhui Zeng, Keke Chen, Xin Tian, Runying Zou, Xiaoqin Feng, Chunfu Li, Jian Li, Mincui Zheng, Huirong Mai, Lihua Yang, Yingyi He, Honggui Xu, Hong Wen & Xiangling He. (2023)
Clinical characteristics and prognosis analysis of patients with de novo
ASXL1
‐mutated
AML
treated with the
C‐HUNAN‐AML
‐15 protocol: A multicenter study by the South China Pediatric
AML
Collaborative Group
. Cancer Medicine 12:12, pages 13182-13192.
Crossref
Crossref
T. N. Subbotina, I. E. Maslyukova, K. S. Semashchenko, G. A. Khodos, D. V. Kurochkin, A. A. Shalyova, M. A. Mikhalev, E. V. Vasiliev, M. G. Osadchaya, E. A. Dunaeva, A. S. Esman & K. O. Mironov. (2023) Analysis of somatic mutations in the <i>JAK2</i>, <i>CALR</i>, <i>MPL</i> and <i>ASXL1</i> genes and evaluation of their impact on the survival of patients with myelofibrosis. Oncohematology 18:1, pages 63-75.
Crossref
Crossref
Ivanna Maikut-Zabrodskaya. (2022) Medium-mass Molecules in Plasma of Patients at Different Stages of Chronic Myeloid Leukemia Progression. Family medicine. European practices:3, pages 73-77.
Crossref
Crossref
Edward A. Medina, Caroline R. Delma & Feng-Chun Yang. (2022) ASXL1/2 mutations and myeloid malignancies. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Mahmut B Koyuncu, Mustafa Ilgan, Hakan Basir, Anil Tombak, Mehmet Ali Ucar, Tolga Koseci, Aydan Akdeniz, Eyup N Tiftik & Özcan Erel. (2022) Ruxolitinib Reduces Oxidative Stress in Patients With Primary Myelofibrosis: A Multicenter Study. Cureus.
Crossref
Crossref
Cristina Panuzzo, Elisabetta Signorino, Chiara Calabrese, Muhammad Shahzad Ali, Jessica Petiti, Enrico Bracco & Daniela Cilloni. (2020) Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia. Journal of Clinical Medicine 9:3, pages 802.
Crossref
Crossref
Serena Salehzadeh, Francesca Guerrini, Umberto Pizzano, Susanna Grassi, Elena Ciabatti, Lorenzo Iovino, Gabriele Buda, Francesco Caracciolo, Edoardo Benedetti, Enrico Orciuolo, Matteo Pelosini, Giovanni Consani, Giovanni Carulli, Maria Rita Metelli, Francesca Martini, Francesco Mazziotta, Elisa Mazzantini, Pietro Rossi, Rita Tavarozzi, Federica Ricci, Mario Petrini & Sara Galimberti. (2019) The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. Cancer Cell International 19:1.
Crossref
Crossref
Lyubov Borisovna Polushkina, V.A. Shuvaev, M.S. Fominykh, Yu.A. Krivolapov, E.A. Belyakova, Z.P. Asaulenko, E.V. Motyko, L.S. Martynenko, M.P. Bakai, N.Yu. Tsybakova, S.V. Voloshin, S.S. Bessmeltsev, A.V. Chechetkin & I.S. Martynkevich. (2019) Current Genetic Models for Prediction of Primary Myelofibrosis. Clinical oncohematology 12:4, pages 31-37.
Crossref
Crossref
Dorota Link-Lenczowska, Łukasz Dryja, Barbara Zapała, Dorota Krochmalczyk & Tomasz Sacha. (2018) Wykrywanie mutacji w genie CALR oraz w genie ASXL1 u chorych na nadpłytkowość samoistną i samoistne włóknienie szpiku przy pomocy sekwencjonowania Sangera oraz analizy długości fragmentów DNA. Acta Haematologica Polonica 49:3, pages 128-139.
Crossref
Crossref
Shuhei Asada, Susumu Goyama, Daichi Inoue, Shiori Shikata, Reina Takeda, Tsuyoshi Fukushima, Taishi Yonezawa, Takeshi Fujino, Yasutaka Hayashi, Kimihito Cojin Kawabata, Tomofusa Fukuyama, Yosuke Tanaka, Akihiko Yokoyama, Satoshi Yamazaki, Hiroko Kozuka-Hata, Masaaki Oyama, Shinya Kojima, Masahito Kawazu, Hiroyuki Mano & Toshio Kitamura. (2018) Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nature Communications 9:1.
Crossref
Crossref
Hongzhuang Peng, Jeremy Prokop, Jayashree Karar, Kyewon Park, Li Cao, J. William Harbour, Anne M. Bowcock, S. Bruce Malkowicz, Mitchell Cheung, Joseph R. Testa & Frank J. RauscherIIIIII. (2018)
Familial and Somatic
BAP1
Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains
. Cancer Research 78:5, pages 1200-1213.
Crossref
Crossref
Agata M. Bogusz. (2017)
EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in
ASXL1
,
BCOR
,
CDKN2A
,
NF1
, and
TP53
. Case Reports in Hematology 2017, pages 1-8.
Crossref
Crossref